95% of healthcare firms beat EPS estimates this week

Earnings
โดย Seeking Alpha·US·Read original
Summary · why it matters

Twenty-one out of 22 healthcare companies that reported quarterly earnings this week delivered better-than-expected earnings per share, with Pfizer, Merck, and Eli Lilly among the major names topping Wall Street forecasts. Pfizer posted adjusted EPS of $0.77 on revenue of $15.03 billion and raised its full-year revenue guidance by $500 million at the midpoint to a range of $60.5 billion to $62.5 billion. Merck reported an adjusted loss of $0.13 per share while revenue rose 5.1% year over year to $16.61 billion, driven by Keytruda sales of $8.4 billion. Eli Lilly’s adjusted EPS jumped roughly 33% to $8.38 on revenue of $23 billion, powered by its GLP-1 portfolio including Zepbound and Mounjaro. Vertex Pharmaceuticals was the only firm to miss earnings estimates, while Zoetis and STERIS fell short on revenue.

Impact on stocks 8

Biotech & Genomic Medicine± Mixed · 4 stocks
Eli Lilly and Company
LLY
▲ PositiveCapitalrelevance

Eli Lilly beat EPS estimates with adjusted EPS up 33% to $8.38 on revenue of $23 billion, driven by GLP-1 portfolio.

Merck & Company Inc
MRK
▲ PositiveCapitalrelevance

Merck reported an adjusted loss but revenue rose 5.1% to $16.61 billion, beating EPS estimates.

Pfizer Inc
PFE
▲ PositiveCapitalrelevance

Pfizer beat EPS estimates with adjusted EPS of $0.77 and raised full-year revenue guidance.

Health Care▼ · 3 stocks
STERIS plc
STE
▼ NegativeCapitalrelevance

STERIS fell short on revenue, missing expectations.

Zoetis Inc
ZTS
± MixedCapitalrelevance

Zoetis fell short on revenue, but the article does not specify the impact on earnings or stock direction.

Critical Materials & Supply Chain▲ · 1 stocks
© 2026 MarketDXNews